Welcome to our dedicated page for LSPR news (Ticker: LSPR), a resource for investors and traders seeking the latest updates and insights on LSPR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LSPR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LSPR's position in the market.
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has successfully completed its business combination with Larkspur Health Acquisition Corp. on December 12, 2022. This merger allows ZyVersa to leverage new funds to advance clinical programs for its product candidates, including VAR 200 for renal disease and IC 100 for inflammatory diseases. ZyVersa will start trading on the NASDAQ under the ticker symbol ZVSA on December 13, 2022. The deal was approved by Larkspur's stockholders on December 8, 2022, marking a significant milestone for ZyVersa.
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. announce participation in the 4th Inflammasome Therapeutics Summit in Boston on November 30-December 1, 2022. ZyVersa’s CEO, Stephen Glover, will chair a CEO panel discussing drug development for inflammasome inhibitors. The company is developing IC 100, an ASC inhibitor targeting various inflammatory diseases. ZyVersa's business combination with Larkspur is set for completion in Q4 2022, with the combined entity expected to be listed on NASDAQ under "ZVSA".
Larkspur Health Acquisition Corp. (LSPR) has scheduled a special meeting for stockholders on December 8, 2022, to vote on the proposed merger with ZyVersa Therapeutics. ZyVersa, a clinical stage biopharmaceutical company, focuses on renal and inflammatory diseases. The merger, initially agreed upon on July 20, 2022, aims to create ZyVersa Therapeutics, Inc., which will trade on NASDAQ under the ticker ZVSA in Q4 2022. The SEC declared Larkspur's Form S-4 effective on November 14, 2022, paving the way for the stockholder vote.
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, announced that CEO Stephen C. Glover will be a speaker at BioFlorida's 2022 Annual Conference, from November 2-4 in Miami, Florida. Glover will participate in a CEO panel discussing insights into building a successful biopharma company. The company is focused on developing therapies for renal and inflammatory diseases, with a combination agreement with Larkspur Health Acquisition Corp., expected to finalize in Q4 2022. The new entity will be named ZyVersa Therapeutics and will list under the ticker 'ZVSA' on NASDAQ.
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. announced a definitive business combination agreement on July 20, 2022, which is expected to be completed in Q4 2022. The aggregate committed financing for the business combination now totals $10.0 million, exceeding previous estimates. This includes approximately $8.5 million from a PIPE investment and $1.5 million from an interim financing round. Upon completion, Larkspur will be renamed ZyVersa Therapeutics, Inc. and listed under ticker ZVSA.
ZyVersa Therapeutics has reported promising data on its novel monoclonal antibody, IC 100, a potent inflammasome ASC inhibitor, designed to tackle chronic inflammation linked to neurodegenerative diseases such as Alzheimer's and Parkinson's.
Research conducted by the University of Miami highlights that IC 100 significantly reduces key inflammatory markers in aged mice, showing its potential as a treatment option. The findings support IC 100's dual action on canonical and non-canonical inflammasome pathways, offering hope for effective treatments in inflammatory and renal diseases.
Larkspur Health Acquisition Corp. (NASDAQ: LSPR) has filed a registration statement on Form S-4 with the SEC for its proposed business combination with ZyVersa Therapeutics, announced on July 20, 2022. ZyVersa, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in renal and inflammatory diseases. The transaction, expected to close in Q4 2022, is subject to SEC approval and shareholder consent. Upon completion, the combined entity will operate as ZyVersa Therapeutics, Inc., trading under symbol 'ZVSA.'
ZyVersa Therapeutics and Larkspur Health Acquisition Corp announced the publication of research data regarding the mechanism of action of IC 100, a novel monoclonal antibody inflammasome ASC inhibitor. Conducted by scientists at the University of Miami, the study highlights IC 100's ability to block inflammasome activation, potentially treating various inflammatory diseases. It shows broad tissue distribution, including the CNS, and may have applications in conditions such as multiple sclerosis and Alzheimer's disease.
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. announced a definitive business combination agreement to become a publicly traded company. This transaction aims to provide ZyVersa with approximately $83.12 million in cash proceeds, enhancing their clinical development of renal treatment VAR 200 and anti-inflammatory drug IC 100. The combined company's initial enterprise value is estimated at $108.92 million, with completion expected by Q4 2022. ZyVersa will trade on NASDAQ under the ticker ZVSA.
FAQ
What is the market cap of LSPR (LSPR)?
